Skip to main content

Table 2 DVH-parameters

From: Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer

Structure

Metric

Median ± Interquartile range (min—max)

Original treatment plan

IGRT

Isoeffective ART

Isotoxic ART

GTV

D95% (Gy)

60.5 ± 0.9

(59.0–62.3)

60.5 ± 2.0

(41.4–63.3)*

60.4 ± 1.6

(58.0–63.6)*

70.5 ± 9.4

(58.4–122.2)*

Rel. D95% (%)

100.0

100.2 ± 1.4

(68.4–103.9)*

99.9 ± 1.9

96.8–105.0)*

116.0 ± 13.5

(96.3–236.8)*

EQD2 (D95%) (Gy)

60.6 ± 1.1

(58.8–62.8)

60.6 ± 2.4

(38.8–64.0)*

60.5 ± 1.9

(57.6–64.3)*

72.9 ± 11.9

(58.1–147.0)*

 

Rel. EQD2 (D95%) (%)

100.0

100.3 ± 1.7

(64.1–104.7)*

99.9 ± 2.2

(96.1–106.0)*

119.6 ± 17.0

(95.4–234.0)*

PTV

D95% (Gy)

60.0 ± 0.0

(56.0–60.0)

57.9 ± 5.8

(16.4–62.1)*

60.0 ± 0.0

(55.8–60.2)

65.5 ± 8.1

(53.5–100.0)*

Rel. D95% (%)

100.0

97.1 ± 7.3

(27.4–104.9)*

100.0 ± 0.1

(99.8–100.2)

109.2 ± 12.0

(94.2–221.3)*

EQD2 (D95%) (Gy)

60.0 ± 0.1

(56.0–60.0)

58.7 ± 6.8

(14.1–62.5)*

60.0 ± 0.0

(55.8–60.2)

66.4 ± 9.8

(52.3–113.1)*

 

Rel. EQD2 (D95%) (%)

100.0

98.8 ± 8.6

(23.5–105.9)*

100.0 ± 0.1

(99.8–100.3)

110.6 ± 14.8

(92.3–188.6)*

Lungipsilateral

MLD (Gy)

14.2 ± 2.4

(7.8–16.9)

14.7 ± 3.0

(7.7–21.8)*

12.3 ± 3.4

(6.6–17.7)*

13.8 ± 2.5

(7.3–20.6)*

Rel. MLD (%)

100.0

103.6 ± 12.7

(23.5–105.9)*

92.8 ± 10.6

(99.8–100.3)*

99.2 ± 3.4

(92.3–188.6)*

V20Gy (%)

30.2 ± 12.3

(13.0–36.9)

31.3 ± 10.0

(12.7–48.8)*

26.6 ± 14.6

(10.7–40.7)*

30.2 ± 12.4

(13.0–37.0)

 

Rel. V20Gy (%)

100.0

105.2 ± 14.7

(74.1–141.8)*

90.7 ± 14.4

(67.9–116.3)*

100.0 ± 0.0

(99.6–100.3)

Lungcontralateral

MLD (Gy)

6.2 ± 4.4

(3.0–12.9)

6.7 ± 4.8

(2.7–13.7)*

6.0 ± 4.9

(2.2–12.9)*

6.5 ± 4.9

(2.6–13.6)*

 

Rel. MLD (%)

100.0

105.1 ± 13.9

(88.1–150.1 *

96.7 ± 10.8

(71.6–124.3)*

102.7 ± 17.6

(73.7–146.8)*

Heart

MHD (Gy)

6.2 ± 5.0

(0.8–9.4)

6.3 ± 5.3

(0.8–15.0)*

5.8 ± 5.4

(0.55–13.0)*

6.2 ± 5.6

(0.8–14.0)*

Rel. MHD (%)

100.0

100.0 ± 32.7

(53.6–257.2)*

90.4 ± 20.1

(49.0–164.8)*

100.0 ± 30.1

(46.4–196.1)*

V5Gy (%)

34.7 ± 24.4

(9.3–59.1)

34.8 ± 26.4

(6.8–100.0)*

30.0 ± 21.7

(4.4–100.0)*

30.8 ± 20.7

(4.5–100.0)*

 

Rel. V5Gy (%)

100.0

100.5 ± 23.6

(53.8–187.3)*

90.7 ± 19.3

(48.3–169.3)*

93.0 ± 29.7

(55.3–180.4)*

Esophagus

MED (Gy)

11.9 ± 9.4

(4.0–24.7)

12.5 ± 11.6

(2.9–27.5)*

11.0 ± 10.5

(2.9–25.7)*

11.1 ± 9.4

(2.7–25.1)*

 

Rel. MED (%)

100.0

102.7 ± 16.1

(51.3–134.6)*

97.2 ± 17.6

(32.0–130.1)*

96.5 ± 22.3

(35.7–147.6)*

Spinal Cord

D0.1% (Gy)

20.3 ± 6.1

(11.3–26.1)

21.3 ± 5.9

(10.6–37.6)*

20.4 ± 6.4

(8.8–29.8)*

21.2 ± 6.8

(7.8–31.0)*

 

Rel. D0.1% (%)

100.0

105.1 ± 11.1

(84.7–209.8)*

102.1 ± 15.3

(66.1–140.3)*

104.8 ± 16.1

(68.3–188.1)*

  1. The absolute and relative median values of the DVH-parameters ± Interquartile ranges as well as (minimum-, maximum doses) for the gross target volume (GTV), planning target volume (PTV) and organs at risk are presented for the dose distributions of the following scenarios: original treatment plan (sCT1), after IGRT (sCT1−n), with isoeffective ART (sCT1−n), with isotoxic ART (sCT1−n). The abbreviations EQD2, MLD, MHD and MED are short for the equivalent dose in 2 Gy-fractions, mean lung dose, mean heart dose and mean esophagus dose, respectively. Statistically significant differences to the initial treatment plans are marked with an asterisk (*)
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us